Objective—The purpose of this study was to test the association between polymorphisms in
genes involved in either LDL cholesterol (LDL-C) metabolism or statin pharmacokinetics …

We carried out a genome-wide association study (GWAS) of LDL-c response to statin using
data from participants in the Collaborative Atorvastatin Diabetes Study (CARDS; n= 1,156) …

Background—There is interindividual variation in low-density lipoprotein cholesterol (LDLc)
lowering by statins and limited study into the genetic associations of the dose dependant …

Aims Statins reduce LDL cholesterol (LDL-C) and the risk of vascular events, but it remains
uncertain whether there is clinically relevant genetic variation in their efficacy. This study of …

Background—In statin trials, each 20 mg/dL reduction in cholesterol results in a 10–15%
reduction of annual incidence rates for vascular events. However, interindividual variation in …

What is known and objective Statins form the backbone of lipid‐lowering therapy for the
prevention of cardiovascular disease. However, there is large interindividual variability in …

ContextPolymorphisms in genes involved in cholesterol synthesis, absorption, and transport
may affect statin efficacy. ObjectiveTo evaluate systematically whether genetic variation …

Aims: Despite the fact that statin treatment efficacy is very high, there are substantial
differences in treatment effectiveness among individuals. It is supposed that genetic …

While conventional pharmacogenetic studies have considered single gene effects, we
tested if a genetic score of nine LDL-and HDL-associated single nucleotide polymorphisms …

Statins are widely prescribed and are established as first-line therapy for the primary and
secondary prevention of coronary artery disease. However, the benefit of treatment varies …